How Leaky Gut Triggers Autoimmune Disease and Chronic Inflammation

That burning sensation creeping up the throat after meals, the belly that balloons by evening, the endless cycle of antacids that stop working, sound familiar? For many people dealing with acid reflux and chronic bloating, the answer may not lie in the stomach at all. It could originate in a compromised gut barrier that has been quietly triggering symptoms all along.

Increased intestinal permeability, sometimes referred to as “leaky gut” in functional medicine contexts, can create a domino effect throughout the digestive system. When the protective lining of the intestines becomes compromised, it may contribute to gastroesophageal reflux disease (GERD), persistent bloating, and a host of systemic symptoms that appear unrelated to digestion. It is important to note that “leaky gut syndrome” is not a formally recognised diagnosis in conventional medicine; rather, increased intestinal permeability is a measurable physiological phenomenon under active clinical research.

Understanding this connection changes the treatment approach. Instead of only masking symptoms, addressing factors that undermine intestinal barrier integrity may offer more lasting relief.

What Is Leaky Gut and How Does It Work?

The intestinal lining functions as a carefully regulated barrier, a security checkpoint that determines what enters the bloodstream and what remains confined to the gut. When functioning properly, nutrients pass through while bacteria, toxins, and undigested food particles are kept out.

Increased intestinal permeability occurs when the tight junctions between intestinal epithelial cells become loose or damaged, allowing undigested food proteins, bacterial fragments, and other molecules to trigger systemic immune responses.

A protein called zonulin plays a central role in regulating tight junction integrity. Research has explored zonulin as a potential biomarker for intestinal permeability; however, important methodological limitations exist. A 2019 Monash University study in PLoS ONE (Ajamian et al.) found that widely used commercial zonulin assays may not detect the actual zonulin protein, instead detecting proteins such as haptoglobin. A further pilot study in Nutrition Research (Tatucu-Babet et al., 2020) found no significant correlation between commercial serum zonulin readings and gold-standard intestinal permeability measurements. Clinicians and patients should interpret commercial zonulin test results cautiously until assay methodology matures.

Several factors have been associated with increased intestinal permeability, as reviewed in research on intestinal barrier function and systemic health (Di Tommaso et al., 2021):

• Small intestinal bacterial overgrowth (SIBO) or fungal overgrowth (SIFO)
• Chronic low-grade inflammation linked to poor diet or food sensitivities
• Prolonged use of NSAIDs or antibiotics
• Chronic psychological stress
• Gut microbiome imbalance (dysbiosis)

When the gut barrier is compromised, symptoms can extend well beyond digestion. Many people report skin conditions such as eczema, cognitive fog, joint discomfort, new-onset food sensitivities, and persistent fatigue, reflecting systemic immune activation.

The Connection Between Leaky Gut and Acid Reflux

The relationship between intestinal permeability and acid reflux is not immediately obvious, but the underlying mechanisms are clinically meaningful. When gut barrier integrity is impaired, conditions are created that can worsen reflux significantly.

Increased intestinal permeability often co-occurs with gut dysbiosis, including small intestinal bacterial overgrowth (SIBO). In SIBO, bacteria that normally reside in the colon migrate into the small intestine, ferment carbohydrates, and produce excess gas. This accumulation increases intra-abdominal pressure, pushing stomach contents upward against the lower esophageal sphincter (LES), the valve that normally keeps stomach acid contained.

Research supports this bidirectional connection. A 2023 review in Pharmacological Reports (Kiecka & Szczepanik) confirmed that long-term acid suppression is an independent risk factor for SIBO, and that the SIBO–GERD relationship is bidirectional, each condition may perpetuate the other. Addressing SIBO in affected patients has shown promise for reducing reflux symptoms, though the degree of improvement varies and large-scale trials are ongoing.

Gut barrier dysfunction may also affect stomach acid production. Many people with intestinal permeability issues exhibit hypochlorhydria (low stomach acid), meaning food digests poorly and lingers in the stomach, increasing reflux risk and reducing the antimicrobial barrier that prevents bacterial migration into the small intestine.

How SIBO Creates the Perfect Storm for Reflux and Bloating

SIBO can be both a cause and a consequence of gut barrier dysfunction, and it directly worsens acid reflux. Bacterial fermentation of carbohydrates in the small intestine produces hydrogen and methane gas, increasing abdominal distension and pressure, pushing stomach contents toward the esophagus.

SIBO also disrupts the migrating motor complex (MMC), the interdigestive motility pattern that sweeps the small intestine between meals. Research in the Journal of Clinical and Experimental Hepatology (Ghosh & Jesudian, 2018) confirms that impaired MMC function is both a risk factor for and consequence of SIBO, creating a self-reinforcing cycle that sustains both overgrowth and gut barrier dysfunction.

SIBO is significantly overrepresented among patients diagnosed with IBS. A systematic review in Gut and Liver (Ghoshal et al., 2017) found SIBO prevalence among IBS patients ranging from 4% to 78% depending on diagnostic criteria and testing method, underscoring how many patients may receive an IBS diagnosis without being tested for underlying bacterial overgrowth. Hydrogen breath testing remains the most accessible non-invasive diagnostic tool, though sensitivity and specificity vary.

Why Low Stomach Acid Makes Everything Worse

Contrary to popular belief, many people with chronic reflux have insufficient stomach acid rather than excess. Healthy gastric acid (pH approximately 1.5–3.5) is essential for protein breakdown, activating digestive enzymes such as pepsin, signalling the LES to remain tightly sealed, and providing an antimicrobial barrier.

When stomach acid is low (hypochlorhydria), several problems cascade:

• Incomplete protein digestion. Undigested food stagnates in the stomach, ferments, produces gas, and can be pushed upward into the esophagus.
• Impaired LES signalling. Adequate gastric acidity helps trigger the sphincter seal. Without it, the valve may not close firmly.
• Increased bacterial survival. Stomach acid destroys many ingested bacteria. Reduced acidity allows more bacteria to survive transit and potentially seed SIBO.

Common contributors to hypochlorhydria include chronic stress, advancing age, hypothyroidism, zinc or B-vitamin deficiencies, and long-term PPI use. A 2024 study in Advances in Pharmacological and Pharmaceutical Sciences (Lim et al.) found that approximately 30% of elderly patients on long-term acid suppressants tested positive for SIBO by glucose breath test, with PPI use independently associated with SIBO-related symptom burden, meaning PPIs can perpetuate the very reflux cycle they were prescribed to manage.

Because hypochlorhydria symptoms closely mimic those of excess acid, professional evaluation before initiating or continuing acid suppression therapy is essential.

SIBO vs. SIFO: Understanding the Difference and Why It Matters

Small intestinal fungal overgrowth (SIFO) closely resembles SIBO in presentation but requires a different treatment approach. Both cause bloating, gas, and abdominal discomfort; both can contribute to gut barrier compromise. Several clinical clues help distinguish them.

SIFO typically involves Candida species in the small intestine. A University of Iowa study in Alimentary Pharmacology & Therapeutics (Jacobs et al., 2013) identified SIFO in 26% of a selected group of patients with unexplained GI symptoms evaluated by duodenal aspirate culture, with dysmotility and PPI use as independent risk factors. This was a specialised clinical cohort, not the general population, and findings should be interpreted in that context.

Distinguishing features that may point toward SIFO include:

• Recurrent fungal infections: vaginal yeast infections, oral thrush, toenail fungus, or persistent fungal rashes
• Intense, difficult-to-control cravings for sugar or refined carbohydrates
• Symptoms that briefly improve on antibiotics, then rapidly relapse or worsen
• Bloating after low-fermentable foods that would not typically provoke SIBO symptoms

Standard SIBO breath tests measure hydrogen and methane produced by bacteria, fungi do not produce these gases, so SIFO will not appear on a breath test. A negative breath test despite ongoing overgrowth-like symptoms may warrant investigation for a fungal component. A healthcare provider can advise on whether empirical antifungal therapy is appropriate.

Diet Strategies That Support Healing Without Backfiring

Diet plays a significant role in managing these conditions, but overly restrictive approaches require careful consideration for long-term gut health.

The Low-FODMAP Dilemma

The low-FODMAP diet reduces bloating and gas by temporarily limiting fermentable carbohydrates. However, it is designed as a short-term therapeutic tool, typically 6–8 weeks, not a permanent dietary pattern, as fermentable fibres are also prebiotic substrates for beneficial gut bacteria.

A randomised controlled trial in The American Journal of Gastroenterology (Wilson et al., 2020) found that a four-week low-FODMAP diet significantly reduced fecal Bifidobacteria and butyrate, a short-chain fatty acid critical for gut barrier integrity, concluding that strict long-term use should not be advised.

Encouragingly, a follow-up study by Staudacher et al. (2021) in Neurogastroenterology and Motility found that after personalised FODMAP reintroduction, Bifidobacteria levels were not significantly different from baseline, suggesting that systematic reintroduction may normalise the short-term microbiome effects.

The Carnivore Caution

Carnivore-style diets provide short-term relief by eliminating all fermentable carbohydrates. However, beneficial bacteria are also deprived of fibre substrates needed for butyrate production. Short-term use followed by gradual reintroduction of diverse plant fibres is a more sustainable strategy.

Practical Eating Strategies

• Space meals 4–5 hours apart to allow the MMC to complete its interdigestive sweep of the small intestine.
• Avoid large volumes of liquid with meals, excessive fluid dilutes gastric acid and digestive enzymes.
• Practise mindful portion control to avoid overwhelming digestive capacity.
• Identify personal trigger foods. Common culprits include legumes, certain raw vegetables, dairy, artificial sweeteners, and highly processed foods, though responses vary widely.

Rebuilding Beneficial Bacteria

Once overgrowth is treated and acute symptoms subside, gradually reintroducing prebiotic fibres, resistant starches from cooked-and-cooled potatoes or rice, small amounts of garlic and onion if tolerated, and diverse vegetables, supports restoration of microbial populations that produce butyrate and sustain gut barrier integrity.

The Bottom Line

The gut has a remarkable capacity to heal with appropriate support. Increased intestinal permeability can respond to targeted interventions, addressing underlying SIBO or SIFO, supporting adequate stomach acid, restoring microbiome diversity, and following a sustainable dietary approach.

If you are experiencing persistent digestive symptoms, working with a qualified healthcare provider, such as a gastroenterologist or registered dietitian with expertise in gut health, is the most important first step before attempting any of the strategies discussed here.

For deeper insights into digestive health and root-cause approaches, Reflux Summit offers expert interviews and evidence-based education.